168 related articles for article (PubMed ID: 28260091)
1. Tetrandrine prevents multidrug resistance in the osteosarcoma cell line, U-2OS, by preventing Pgp overexpression through the inhibition of NF-κB signaling.
Lu Y; Li F; Xu T; Sun J
Int J Mol Med; 2017 Apr; 39(4):993-1000. PubMed ID: 28260091
[TBL] [Abstract][Full Text] [Related]
2. Prevention of multidrug resistance (MDR) in osteosarcoma by NSC23925.
Yang X; Yang P; Shen J; Osaka E; Choy E; Cote G; Harmon D; Zhang Z; Mankin H; Hornicek FJ; Duan Z
Br J Cancer; 2014 Jun; 110(12):2896-904. PubMed ID: 24853187
[TBL] [Abstract][Full Text] [Related]
3. The novel inhibitor BRM270 downregulates tumorigenesis by suppression of NF-κB signaling cascade in MDR-induced stem like cancer-initiating cells.
Mongre RK; Sodhi SS; Ghosh M; Kim JH; Kim N; Park YH; Kim SJ; Heo YJ; Sharma N; Jeong DK
Int J Oncol; 2015; 46(6):2573-85. PubMed ID: 25872586
[TBL] [Abstract][Full Text] [Related]
4. NSC23925 prevents the emergence of multidrug resistance in ovarian cancer in vitro and in vivo.
Yang X; Feng Y; Gao Y; Shen J; Choy E; Cote G; Harmon D; Zhang Z; Mankin H; Hornicek FJ; Duan Z
Gynecol Oncol; 2015 Apr; 137(1):134-42. PubMed ID: 25677062
[TBL] [Abstract][Full Text] [Related]
5. [Effects of tetrandrine on nuclear factor-kappaB expression in leukemia multidrug-resistant cell line K562/A02].
Chen BA; Su AL; Cheng J; Zhao HH; Li GH; Wang XM
Zhong Xi Yi Jie He Xue Bao; 2008 Sep; 6(9):956-9. PubMed ID: 18782542
[TBL] [Abstract][Full Text] [Related]
6. H1, a novel derivative of tetrandrine reverse P-glycoprotein-mediated multidrug resistance by inhibiting transport function and expression of P-glycoprotein.
Wei N; Sun H; Wang F; Liu G
Cancer Chemother Pharmacol; 2011 May; 67(5):1017-25. PubMed ID: 20640574
[TBL] [Abstract][Full Text] [Related]
7. Alopecurone B reverses doxorubicin-resistant human osteosarcoma cell line by inhibiting P-glycoprotein and NF-kappa B signaling.
Xia YZ; Ni K; Guo C; Zhang C; Geng YD; Wang ZD; Yang L; Kong LY
Phytomedicine; 2015 Mar; 22(3):344-51. PubMed ID: 25837271
[TBL] [Abstract][Full Text] [Related]
8. [Effect of tetrandrine in combination with droloxifen on the expression of NF-kappaB protein in K562 and K562/A02 cell lines].
Su AL; Chen BA; Huang CY; Gao F; Cheng J; Xu WL; Shen HL; Sun XC; Cheng HY; Ding JH; Gao C; Sun YY; Wang J; Zhao G; Chen NN; Zhao HH
Zhonghua Xue Ye Xue Za Zhi; 2008 May; 29(5):321-4. PubMed ID: 18844070
[TBL] [Abstract][Full Text] [Related]
9. Targeting ABCB1 and ABCC1 with their Specific Inhibitor CBT-1® can Overcome Drug Resistance in Osteosarcoma.
Fanelli M; Hattinger CM; Vella S; Tavanti E; Michelacci F; Gudeman B; Barnett D; Picci P; Serra M
Curr Cancer Drug Targets; 2016; 16(3):261-74. PubMed ID: 26548759
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of IL-6 but not IL-8 increases paclitaxel resistance of U-2OS human osteosarcoma cells.
Duan Z; Lamendola DE; Penson RT; Kronish KM; Seiden MV
Cytokine; 2002 Mar; 17(5):234-42. PubMed ID: 12027404
[TBL] [Abstract][Full Text] [Related]
11. Tetrandrine prevents acquired drug resistance of K562 cells through inhibition of mdr1 gene transcription.
Shen H; Xu W; Chen Q; Wu Z; Tang H; Wang F
J Cancer Res Clin Oncol; 2010 May; 136(5):659-65. PubMed ID: 19898868
[TBL] [Abstract][Full Text] [Related]
12. Co-delivery of paclitaxel and tetrandrine via iRGD peptide conjugated lipid-polymer hybrid nanoparticles overcome multidrug resistance in cancer cells.
Zhang J; Wang L; Fai Chan H; Xie W; Chen S; He C; Wang Y; Chen M
Sci Rep; 2017 May; 7():46057. PubMed ID: 28470171
[TBL] [Abstract][Full Text] [Related]
13. A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells.
Duan Z; Zhang J; Ye S; Shen J; Choy E; Cote G; Harmon D; Mankin H; Hua Y; Zhang Y; Gray NS; Hornicek FJ
BMC Cancer; 2014 Sep; 14():681. PubMed ID: 25236161
[TBL] [Abstract][Full Text] [Related]
14. Multidrug resistance reversal agent, NSC77037, identified with a cell-based screening assay.
Susa M; Choy E; Yang C; Schwab J; Mankin H; Hornicek F; Duan Z
J Biomol Screen; 2010 Mar; 15(3):287-96. PubMed ID: 20150589
[TBL] [Abstract][Full Text] [Related]
15. Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine.
Jin J; Wang FP; Wei H; Liu G
Cancer Chemother Pharmacol; 2005 Feb; 55(2):179-88. PubMed ID: 15378274
[TBL] [Abstract][Full Text] [Related]
16. Reversion of P-glycoprotein-mediated multidrug resistance by diallyl trisulfide in a human osteosarcoma cell line.
Wang Z; Xia Q; Cui J; Diao Y; Li J
Oncol Rep; 2014 Jun; 31(6):2720-6. PubMed ID: 24788927
[TBL] [Abstract][Full Text] [Related]
17. Activation of TNF-α/NF-κB axis enhances CRL4B
Zhang C; Chen B; Jiang K; Lao L; Shen H; Chen Z
Mol Oncol; 2018 Apr; 12(4):476-494. PubMed ID: 29377600
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo characterizations of tetrandrine on the reversal of P-glycoprotein-mediated drug resistance to paclitaxel.
Zhu X; Sui M; Fan W
Anticancer Res; 2005; 25(3B):1953-62. PubMed ID: 16158930
[TBL] [Abstract][Full Text] [Related]
19. The novel bis-benzylisoquinoline PY35 reverses P-glycoprotein-mediated multidrug resistance.
Cao Z; Wright M; Cheng J; Huang X; Liu L; Wu L; Yang P
Oncol Rep; 2014 Sep; 32(3):1211-7. PubMed ID: 25017650
[TBL] [Abstract][Full Text] [Related]
20. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
